FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a heterocyclic compound of formula (I) and a pharmaceutically acceptable salt thereof, where R1, R2, R3 and R4 are independently selected from H and C1-C4-alkyl; R5, R7 and R9 are independently selected from H and C1-C4-alkyl; R8 and R11 together form -CH2-CH2-; R10 is H, or R10 and R11 together form - (CH2)w-; or R6 and R9 together form -CH2-, R8 is H, and R10 and R11 together form -CH2-; A is -C(O) - or -S(O)2-; R12 is C1-C4-alkyl; R13 is halogen or cyano; R14 is H or C1-C4-alkyl; R15 is H or C1-C4-alkyl; m, n and p are independently selected from 0 and 1; w is 1, 2 or 3. Invention also relates to a pharmaceutical composition based on the compound of formula (I), use of the compound of formula (I) and a method of treating or preventing chronic renal disease, congestive heart failure, hypertension, primary aldosterone and Cushing syndrome.
EFFECT: technical result is obtaining novel heterocyclic compounds having aldosterone synthase inhibitory activity.
28 cl, 2 tbl, 47 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS 3,4-DIHYDRO-2N-ISOQUINOLIN-1-ONE AND 2,3-DIHYDROISOINDOL-1-ONE | 2014 |
|
RU2693698C2 |
| NOVEL 3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONES AND 2,3-DIHYDRO-ISOINDOLE-1-ONES | 2014 |
|
RU2689421C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2789610C1 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2022 |
|
RU2811745C1 |
| AROYLAMINO- AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | 2010 |
|
RU2517701C2 |
| IMIDAZO[1,2-A]PYRAZIN-1-YL-BENZAMIDES FOR TREATING SPINAL MUSCULAR ATROPHY | 2015 |
|
RU2725979C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
| ALDOSTERONE SYNTHASE INHIBITORS BASED ON 2-AMINO-4H-PYRAN-3-CARBONITRILE DERIVATIVES | 2019 |
|
RU2717310C1 |
| DERIVATIVES OF [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE WITH AFFINITY TO CANNABINOID RECEPTORS OF TYPE 2 | 2017 |
|
RU2741597C2 |
